Skip to content

BIOTRICITY INC.: 10-Q filed 2026-02-11

What BIOTRICITY INC. reported in its quarterly report filed 2026-02-11 (fiscal Q3 2026): 44 published measures, 126 facts as tagged in accession 0001493152-26-006211.

This filing

Form
10-Q (quarterly report)
Filed
2026-02-11
Fiscal period
fiscal Q3 2026
Accession
0001493152-26-006211 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOTRICITY INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-12-315,686,495USD
At 2025-03-315,640,954USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-12-3138,208,764USD
At 2025-03-3135,655,054USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-12-31-34,236,745USD
At 2025-09-30-33,412,378USD
At 2025-03-31-32,014,390USD
At 2024-12-31-31,939,166USD
At 2024-09-30-31,166,835USD
At 2024-03-31-31,465,737USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-12-31256,357USD
At 2025-03-31365,145USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-717,067USD92
2025-04-01 to 2025-12-31-2,079,957USD275
2024-10-01 to 2024-12-31-1,229,154USD92
2024-04-01 to 2024-12-31-6,485,442USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-04-01 to 2025-12-31-698,050USD275
2024-04-01 to 2024-12-31-1,979,392USD275

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-10-01 to 2025-12-313,987,819USD92
2025-04-01 to 2025-12-3111,747,607USD275
2024-10-01 to 2024-12-313,619,108USD92
2024-04-01 to 2024-12-3110,087,697USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-04-01 to 2025-12-31649,282USD275
2024-04-01 to 2024-12-311,764,239USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-12-31-142,116,468USD
At 2025-03-31-139,441,785USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-10-01 to 2025-12-3127,590,766shares92
2025-04-01 to 2025-12-3126,883,125shares275
2024-10-01 to 2024-12-3124,232,369shares92
2024-04-01 to 2024-12-3119,916,489shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-10-01 to 2025-12-3127,590,766shares92
2025-04-01 to 2025-12-3126,883,125shares275
2024-10-01 to 2024-12-3124,232,369shares92
2024-04-01 to 2024-12-3119,916,489shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-0.042USD/shares92
2025-04-01 to 2025-12-31-0.099USD/shares275
2024-10-01 to 2024-12-31-0.054USD/shares92
2024-04-01 to 2024-12-31-0.498USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-0.042USD/shares92
2025-04-01 to 2025-12-31-0.099USD/shares275
2024-10-01 to 2024-12-31-0.054USD/shares92
2024-04-01 to 2024-12-31-0.498USD/shares275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-12-315,134USD
At 2025-03-319,599USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-04-01 to 2025-12-3117,937USD275
2024-04-01 to 2024-12-31172,802USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-10-01 to 2025-12-31440,915USD92
2025-04-01 to 2025-12-31996,679USD275
2024-10-01 to 2024-12-31-168,982USD92
2024-04-01 to 2024-12-31-1,593,500USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-12-314,981,239USD
At 2025-03-314,639,292USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2022-11-01 to 2022-11-30364,000USD30

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-12-3123,796,884USD
At 2025-03-3120,636,148USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-12-311,578,269USD
At 2025-03-311,658,772USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-10-01 to 2025-12-312,810,561USD92
2025-04-01 to 2025-12-318,553,095USD275
2024-10-01 to 2024-12-312,932,950USD92
2024-04-01 to 2024-12-319,179,810USD275

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-12-311,974,758USD
At 2025-03-311,555,385USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-10-01 to 2025-12-313,251,476USD92
2025-04-01 to 2025-12-319,549,774USD275
2024-10-01 to 2024-12-312,763,968USD92
2024-04-01 to 2024-12-317,586,310USD275

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-10-01 to 2025-12-31736,343USD92
2025-04-01 to 2025-12-312,197,833USD275
2024-10-01 to 2024-12-31855,140USD92
2024-04-01 to 2024-12-312,501,387USD275

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-10-01 to 2025-12-312,186,994USD92
2025-04-01 to 2025-12-316,630,567USD275
2024-10-01 to 2024-12-312,381,734USD92
2024-04-01 to 2024-12-317,596,717USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-10-01 to 2025-12-31623,567USD92
2025-04-01 to 2025-12-311,922,528USD275
2024-10-01 to 2024-12-31551,216USD92
2024-04-01 to 2024-12-311,583,093USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-12-3127,807,711shares
At 2025-03-3126,081,295shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-12-31107,615,332USD
At 2025-03-31107,123,300USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-12-31-47,823USD
At 2025-03-31-6,393USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-12-31468,427USD
At 2025-03-31812,053USD
At 2024-03-311,221,593USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-12-31539,398USD
At 2025-03-31929,116USD
At 2024-03-311,386,486USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-12-3129,767USD
At 2025-03-3129,767USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-12-3124,633USD
At 2025-03-3120,168USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-12-313,732,257USD
At 2025-03-313,034,293USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-717,067USD92
2025-04-01 to 2025-12-31-2,079,957USD275
2024-10-01 to 2024-12-31-1,229,154USD92
2024-04-01 to 2024-12-31-6,485,442USD275

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-1,162,614USD92
2025-04-01 to 2025-12-31-2,716,113USD275
2024-10-01 to 2024-12-31-1,241,866USD92
2024-04-01 to 2024-12-31-9,948,980USD275

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-1,148,067USD92
2025-04-01 to 2025-12-31-2,674,683USD275
2024-10-01 to 2024-12-31-1,318,546USD92
2024-04-01 to 2024-12-31-9,919,867USD275

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-04-01 to 2025-12-314,465USD275
2024-04-01 to 2024-12-314,465USD275

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-10-01 to 2025-12-31810,339USD92
2025-04-01 to 2025-12-312,521,012USD275
2024-10-01 to 2024-12-31849,538USD92
2024-04-01 to 2024-12-312,370,286USD275

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-39,247USD92
2025-04-01 to 2025-12-31134,023USD275
2024-10-01 to 2024-12-3165,512USD92
2024-04-01 to 2024-12-31-127,974USD275

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-04-01 to 2025-12-312,494,036USD275
2024-04-01 to 2024-12-312,432,947USD275

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-04-01 to 2024-12-31125,220USD275

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-12-31-28,818USD275
2024-04-01 to 2024-12-31-300,088USD275

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-12-31419,373USD275
2024-04-01 to 2024-12-31-309,317USD275

Inspect the source

Entity
BIOTRICITY INC. / CIK 0001630113
Captured
2026-09-21T17:22:14.606Z
SEC response SHA-256
de56e3354d4180362d8bf36a6dd02ff7fd0db9690bc31c81e452959deb9a8d37

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001630113.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))